Diabetic Retinopathy – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Diabetic Retinopathy – Drugs In Development, 2023’, provides an overview of the Diabetic Retinopathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
- The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
A6 Pharmaceuticals LLCAbbVie Inc
Ailon Co Ltd
Amytrx Therapeutics Inc
Angios GmbH
AntlerA Therapeutics Inc
Applied Therapeutics Inc
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Arctic Vision Shanghai Biotechnology Co Ltd
Aviceda Therapeutics Inc
Bayer AG
BetaStem Therapeutics Inc
Boehringer Ingelheim International GmbH
Bonac Corp
Breye Therapeutics ApS
Caregen Co Ltd
CCRP Therapeutics GmbH
CdmoGen Co Ltd
Cedars-Sinai Medical Center
Cell Care Therapeutics Inc
Charlesson LLC
Clayton Biotechnologies Inc
Connexin Therapeutics Inc
Curative Biotechnology Inc
D-Sight SL
Daegu Gyeongbuk Medical Innovation Foundation
Daewoong Pharmaceutical Co Ltd
Eluminex Biosciences Ltd
Ennovabio
Epigen Biosciences Inc
Essex Bio-Technology Ltd
Everglades Biopharma LLC
Excitant Therapeutics LLC
EyeGene Inc
EyePoint Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Frontbio Co Ltd
Glycadia Inc
Grupo Ferrer Internacional SA
Guangzhou Magpie Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
ImmunAbs Inc
iRegene Therapeutics Co Ltd
jCyte Inc
Kalos Therapeutics Inc
Kanaph Therapeutics Inc
Kato Pharmaceuticals Inc
KP Biosciences Inc
Kriya Therapeutics Inc
Kubota Vision Inc
Laboratorios Salvat SA
Loxagen Inc
Luye Pharma Group Ltd
Mabion SA
MabTics
MD Healthcare Inc
MingSight Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
NanoPharmaceuticals LLC
NB Health Laboratory Co Ltd
NeuMedics Inc
NexThera Co Ltd
NGM Biopharmaceuticals Inc
Novago Therapeutics AG
Novaliq GmbH
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis Holding AG
OcuNexus Therapeutics Inc
Ocuphire Pharma Inc
OcuTerra Therapeutics Inc
Oklahoma Medical Research Foundation
OliPass Corporation
OM Pharma Ltd
Opera Therapeutics
Orpheus BioScience LLC
Osaka University
Oxular Ltd
Palatin Technologies Inc
Perfuse Therapeutics Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Pinotbio Inc
Praetego Inc
Profarma
Ranger Biotechnologies AS
Regenerate Therapeutics Inc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Retinset SL
Retrotope Inc
Revel Pharmaceuticals Inc
Ribomic Inc
SEASUN THERAPEUTICS Inc
Serodus ASA
Shenzhen Evergreen Therapeutics Co Ltd
Shilpa Biologicals Pvt Ltd
SIFI SpA
Singh Biotechnology LLC
SiNOPSEE Therapeutics Pte Ltd
Skyran Biologics Inc
SmartinBio
Starpax Biopharma Inc
SunBio Inc
Sylentis SAU
Talem Therapeutics Inc
Tarsier Pharma Ltd
Teraclon IDF SL
ToolGen Inc
Topadur Pharma AG
Translatum Medicus Inc
Unity Biotechnology Inc
University of California Irvine
University of Florida
University of Montreal
University of New South Wales
University of North Carolina at Chapel Hill
University of Tennessee
USA Elixiria Biotech Inc
Valitor Inc
Vall d’Hebron Institute of Research
Valo Health LLC
Vantage Biosciences Ltd
Vascugen Inc
Verseon Corp
VESSL Therapeutics Ltd
Vitreo Pharma Inc
Xbrane Biopharma AB
Xequel Bio Inc
YD Life Science Co
Zih Yuan Tang Biotechnology Co Ltd